单中心109例慢性粒-单核细胞白血病患者的分子学特征
按WHO 2022分类对2016年3月至2021年10月单中心113例CMML和840例MDS患者重新诊断,23例(20.4%)CMML重新诊断为AML,90例符合WHO 2022 CMML标准,19例(2.3%)MDS符合CMML标准;CMML中99%检出至少1种突变,MD-CMML与MP-CMML分子学特征不同。
要点
- 113例原诊断CMML中23例(20.4%)按WHO 2022重新诊断为AML,包括18例AML伴NPM1突变。
- 99%的CMML患者检出至少1种基因突变,中位突变个数为4(2,5)个。
- SRSF2与ASXL1、TET2常共存突变;U2AF1与TET2常互斥,多见于年轻MD-CMML。
核心结论
- 按照WHO 2022分类,约20%的CMML病例诊断时AMoC<1×10(9)/L,MD-CMML和MP-CMML有不同的分子学特征。
研究设计与样本
- 单中心研究,按照WHO 2022分类对2016年3月至2021年10月113例CMML和840例MDS患者进行CMML重新诊断,并分析符合WHO 2022标准CMML患者的临床和分子学特征。
主要发现
- 113例WHO 2016标准诊断的CMML患者有23例(20.4%)重新诊断为AML,包括18例AML伴NPM1突变、3例AML伴KMT2A重排和2例AML伴MECOM重排;另90例符合WHO 2022 CMML诊断标准。
- 840例MDS患者中有19例(2.3%)符合WHO 2022 CMML诊断标准。
- 99%的CMML患者检出至少1种基因突变,中位突变个数为4(2,5)个。
- 突变检出率≥10%的基因依次为ASXL1(48%)、NRAS(34%)、RUNX1(33%)、TET2(28%)、U2AF1(23%)、SRSF2(21.1%)、SETBP1(20%)、KRAS(17%)、CBL(16%)和DNMT3A(11%)。
- 配对分析显示SRSF2同ASXL1(OR=4.129,95% CI 1.481~11.510,Q=0.007)和TET2(OR=5.276,95% CI 1.979~14.065,Q=0.001)常为共存突变;SRSF2和TET2常出现于老年(≥60岁)MP-CMML患者;U2AF1同TET2(OR=0.174,95% CI 0.038~0.791,Q=0.024)常成互斥关系,易见于年轻(<60岁)MD-CMML患者。
关键数值与推荐
- AMoC≥1×10(9)/L组与AMoC<1×10(9)/L组比较,前者有更高的中位发病年龄(60岁对47岁,P<0.001)、WBC(15.9×10(9)/L对4.4×10(9)/L,P<0.001)、单核细胞比例(21.5%对15%,P=0.001)和HGB水平(86 g/L对74 g/L,P=0.014)。
- TET2突变(P=0.021)和SRSF2突变(P=0.011)更常见于AMoC≥1×10(9)/L组,而U2AF1突变(P<0.001)更常见于AMoC<1×10(9)/L组;两组间的其他基因突变频率差异无统计学意义。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To explore the molecular features of chronic myelomonocytic leukemia (CMML) . Methods: According to 2022 World Health Organization (WHO 2022) classification, 113 CMML patients and 840 myelodysplastic syndrome (MDS) patients from March 2016 to October 2021 were reclassified, and the clinical and molecular features of CMML patients were analyzed. Results: Among 113 CMML patients, 23 (20.4%) were re-diagnosed as acute myeloid leukemia (AML), including 18 AML with NPM1 mutation, 3 AML with KMT2A rearrangement, and 2 AML with MECOM rearrangement. The remaining 90 patients met the WHO 2022 CMML criteria. In addition, 19 of 840 (2.3%) MDS patients met the WHO 2022 CMML criteria. At least one gene mutation was detected in 99% of CMML patients, and the median number of mutations was 4. The genes with mutation frequency ≥ 10% were: ASXL1 (48%), NRAS (34%), RUNX1 (33%), TET2 (28%), U2AF1 (23%), SRSF2 (21.1%), SETBP1 (20%), KRAS (17%), CBL (15.6%) and DNMT3A (11%). Paired analysis showed that SRSF2 was frequently co-mutated with ASXL1 (OR=4.129, 95% CI 1.481-11.510, Q=0.007) and TET2 (OR=5.276, 95% CI 1.979-14.065, Q=0.001). SRSF2 and TET2 frequently occurred in elderly (≥60 years) patients with myeloproliferative CMML (MP-CMML). U2AF1 mutations were often mutually exclusive with TET2 (OR=0.174, 95% CI 0.038-0.791, Q=0.024), and were common in younger (<60 years) patients with myelodysplastic CMML (MD-CMML). Compared with patients with absolute monocyte count (AMoC) ≥1×10(9)/L and <1×10(9)/L, the former had a higher median age of onset (60 years old vs 47 years old, P<0.001), white blood cell count (15.9×10(9)/L vs 4.4×10(9)/L, P<0.001), proportion of monocytes (21.5% vs 15%, P=0.001), and hemoglobin level (86 g/L vs 74 g/L, P=0.014). TET2 mutations (P=0.021) and SRSF2 mutations (P=0.011) were more common in patients with AMoC≥1×10(9)/L, whereas U2AF1 mutations (P<0.001) were more common in patients with AMoC<1×10(9)/L. There was no significant difference in the frequency of other gene mutations between the two groups. Conclusion: According to WHO 2022 classification, nearly 20% of CMML patients had AMoC<1×10(9)/L at the time of diagnosis, and MD-CMML and MP-CMML had different molecular features. 目的: 探索慢性粒-单核细胞白血病(CMML)的基因突变特征。 方法: 按照WHO 2022分类,对2016年3月至2021年10月113例CMML和840例骨髓增生异常综合征(MDS)患者进行CMML重新诊断,并分析符合WHO 2022标准CMML患者的临床和分子学特征。 结果: 113例WHO 2016标准诊断的CMML患者有23例(20.4%)重新诊断为急性髓系白血病(AML),包括18例AML伴NPM1突变,3例AML伴KMT2A重排和2例AML伴MECOM重排。另90例患者符合WHO 2022 CMML诊断标准。840例MDS患者中有19例(2.3%)符合WHO 2022 CMML诊断标准。99%的CMML患者检出至少1种基因突变,中位突变个数为4(2,5)个。突变检出率≥10%的基因依次为:ASXL1(48%)、NRAS(34%)、RUNX1(33%)、TET2(28%)、U2AF1(23%)、SRSF2(21.1%)、SETBP1(20%)、KRAS(17%)、CBL(16%)和DNMT3A(11%)。配对分析显示SRSF2同ASXL1(OR=4.129,95% CI 1.481~11.510,Q=0.007)和TET2(OR=5.276,95% CI 1.979~14.065,Q=0.001)常为共存突变。SRSF2和TET2常出现于老年(≥60岁)增殖型CMML(MP-CMML)患者。U2AF1同TET2(OR=0.174,95% CI 0.038~0.791,Q=0.024)常成互斥关系,易见于年轻(<60岁)发育异常型CMML(MD-CMML)患者。单核细胞绝对值计数(AMoC)≥1×10(9)/L和<1×10(9)/L两组患者比较比较,前者有更高的中位发病年龄(60岁对47岁,P<0.001)、WBC(15.9×10(9)/L对4.4×10(9)/L,P<0.001)、单核细胞比例(21.5%对15%,P=0.001)和HGB水平(86 g/L对74 g/L,P=0.014)。TET2突变(P=0.021)和SRSF2突变(P=0.011)更常见于AMoC≥1×10(9)/L组,而U2AF1突变(P<0.001)更常见于AMoC<1×10(9)/L组。两组间的其他基因突变频率差异无统计学意义。 结论: 按照WHO 2022分类,约20%的CMML病例诊断时的AMoC<1×10(9)/L,MD-CMML和MP-CMML有不同的分子学特征。.
引用
- Qu SQ, Pan LJ, Qin TJ, et al. [Molecular features of 109 patients with chronic myelomonocytic leukemia in a single center]. Zhonghua Xue Ye Xue Za Zhi. 2023. PMID: 37550186. doi:10.3760/cma.j.issn.0253-2727.2023.05.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。